Publication: Coreceptor tropism determined by genotypic assay in HIV-1 circulating in Thailand, where CRF01_AE predominates
Issued Date
2014-01-01
Resource Type
ISSN
14681293
14642662
14642662
Other identifier(s)
2-s2.0-84897436592
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
HIV Medicine. Vol.15, No.5 (2014), 269-275
Suggested Citation
A. Phuphuakrat, S. Phawattanakul, E. Pasomsub, S. Kiertiburanakul, W. Chantratita, S. Sungkanuparph Coreceptor tropism determined by genotypic assay in HIV-1 circulating in Thailand, where CRF01_AE predominates. HIV Medicine. Vol.15, No.5 (2014), 269-275. doi:10.1111/hiv.12108 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34502
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Coreceptor tropism determined by genotypic assay in HIV-1 circulating in Thailand, where CRF01_AE predominates
Other Contributor(s)
Abstract
Objectives: Chemokine (C-C motif) receptor 5 (CCR5) inhibitors are a novel class of antiretroviral agents that are promising for treatment of patients who harbour the HIV-1 R5 strain. Data on coreceptor tropism in non-B HIV-1 subtypes are limited. We studied coreceptor tropism in HIV-1 circulating in Thailand, where CRF01_AE predominates, using a genotypic assay. Methods: We compiled V3 sequences of HIV-1 strains circulating in Thailand during 2010-2012. Coreceptor tropism was predicted based on V3 sequences using geno2pheno version 2.5 (http://coreceptor.bioinf.mpi-inf.mpg.de). Results: One hundred and fifty-five HIV-1-infected patients were enrolled in this study. Ninety-nine patients (63.9%) were antiretroviral-naïve, and the remainder had virological failure. The median (interquartile range) CD4 cell count and HIV-1 RNA were 220 (74-379) cells/μL and 75374 (14127-226686) HIV-1 RNA copies/mL, respectively. Of the sequences obtained from these patients, 119 (76.8%) were CRF01_AE and 22 (14.2%) were subtype B. At a false positive rate of <5%, 61 (39.4%) HIV-1-infected individuals were predicted to harbour the X4 phenotype. X4 viruses were detected more frequently in the treatment-failure group compared with the treatment-naïve group (30.3 vs. 55.4%, respectively; P=0.002). Those with CRF01_AE had a higher proportion of X4 viruses compared with non-AE subtypes (47.9 vs. 11.1%, respectively; P<0.001). By multivariate logistic regression, CRF01_AE and treatment failure were independently associated with predicted X4 phenotype [odds ratio (OR) 7.93; 95% confidence interval (CI) 2.57-24.50; P<0.001, and OR 3.10; 95% CI 1.50-6.42; P=0.002, respectively]. Conclusions: CRF01_AE and treatment failure are associated with the predicted X4 phenotype. In regions where CRF01_AE predominates, use of CCR5 inhibitors must be considered with caution. The phenotypic assay and its correlation with genotypes should be further investigated in CRF01_AE. © 2013 British HIV Association.